About the company
Natera Inc is a leading diagnostic and research company that utilizes its proprietary molecular and bioinformatics technology to provide innovative solutions in the field of personalized medicine. With a focus on genomics and genetic testing, the company offers a range of groundbreaking products and services that have revolutionized the field of prenatal diagnostics, genetic carrier screening, cancer monitoring, and organ transplant assessment. One of Natera's key products is the Panorama Non-Invasive Prenatal Test (NIPT). This test is designed to analyze the fetal DNA present in the mother's blood and screen for a wide range of chromosomal abnormalities, such as Down syndrome, Edwards syndrome, and Patau syndrome. Unlike traditional invasive prenatal tests, like amniocentesis or chorionic villus sampling, Panorama is a non-invasive option that carries no risk to the fetus. It provides expectant parents with crucial information about their baby's health, helping them make informed decisions and plan for any potential medical needs. In addition to prenatal testing, Natera has developed the Horizon Carrier Screening (HCS) test, which aims to identify genetic carrier status for a large number of severe genetic diseases. This screening can provide prospective parents with invaluable insights into their risk of passing on genetic conditions to their children. By detecting potential carrier status before conception, HCS offers informed reproductive planning and can assist in reducing the incidence of genetic diseases. Natera's innovative approach to cancer monitoring and management is facilitated through their Signatera molecular residual disease (MRD) test. This cutting-edge test is employed in patients who have previously been diagnosed with cancer to assess the presence of circulating tumor DNA (ctDNA) in their bloodstream. By utilizing the latest advancements in next-generation sequencing and analyzing the molecular signature of a patient's tumor, Signatera can detect residual cancer cells, monitor treatment response, and detect early signs of cancer recurrence. This highly sensitive and specific test provides oncologists with critical information to personalize and optimize their patients' treatment plans. Another groundbreaking product from Natera is Prospera, which addresses the critical need for improved organ transplant assessments. Transplant rejection is a significant concern following organ transplantation, and with the Prospera test, clinicians can monitor the immune system's response to the transplanted organ. By analyzing cell-free DNA from the blood, Prospera can detect early signs of rejection, enabling timely intervention and potentially improving patient outcomes. In summary, Natera Inc is an innovative company at the forefront of molecular diagnostics. With its range of advanced products and services, the company is shaping the future of personalized medicine. Through their Panorama NIPT, Horizon Carrier Screening, Signatera MRD test, and Prospera, Natera is transforming the way we approach prenatal testing, genetic carrier screening, cancer monitoring, and organ transplant assessments. With their commitment to advancing the field of genomics and genetic testing, Natera is revolutionizing healthcare by delivering personalized solutions that empower patients and healthcare providers alike.
Website: https://www.natera.com
Data updated: June 2, 2026
